NCT06563778 - Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2028

Conditions

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma

Interventions

DRUG

Chidamide; Decitabine; Anti-PD-1 Antibody

Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.

DRUG

Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody

Brentuximab Vedotin 1.2-1.8mg/kg day 1, Bendamustine 70-90mg/m2 day1-2, Anti-PD-1 antibody day 2. Physicians will decide which immune checkpoint inhibitors will be used during treatment.

Trial Locations (1)

100853

Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing

All Listed Sponsors

lead

Chinese PLA General Hospital

OTHER